-
METHYL-D3-AMINE HYDROCHLORIDE (CAS No. 7436-22-8): A Key Deuterated Building Block for Deucravacitinib Intermediate Synthesis
Introduction The rapid advancement of modern pharmaceutical research has significantly increased the demand for stable isotope-labeled compounds. Among these, METHYL-D3-AMINE HYDROCHLORIDE (CAS No. 7436-22-8) has become an essential deuterated reagent widely used in medicinal chemistry, isotope-l...Read more -
How Fluorinated Pyrazolopyridine Intermediates Enable Vericiguat Synthesis: Understanding the Role of Ethyl
5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate Introduction Modern drug discovery increasingly depends on the precise design of complex heterocyclic molecules. In cardiovascular drug development, fluorinated heterocycles have become especially important because fluorine atom...Read more -
How 4-Amino-5-Methylpyridin-2-ol Supports the Manufacturing of Finerenone Intermediates
The Rising Demand for Finerenone Is Creating New Opportunities for Pharmaceutical Intermediate Manufacturers The pharmaceutical industry is witnessing rapid growth in therapies targeting chronic kidney disease (CKD) and cardiovascular complications associated with type 2 diabetes. Among the lates...Read more -
Deucravacitinib 1609392-27-9 Synthesis Process | Mass Production Quality Control and Supply Chain Solutions of Three Core Deuterated Intermediates
Meta Description: Focus on the industrial synthesis route of deuterated lexicotinib (Deucravacitinib), and explain in detail the quality control difficulties and mass production process of key intermediates; Covers deuterated methylamine hydrochloride 7436-22-8, 4,6-dichloro-N-(methyl-d3)-3-pyrid...Read more -
Orforglipron Intermediate Procurement Guide: Pharmaceutical Enterprises Mass Production Pain Point Solutions
1. text difficulties in Industrial Synthesis of Ogleron (CAS:2212020-52-3) and Selection Criteria for Three Key Intermediates core keywords: Ogleron synthesis process, impurity control of Ogleron intermediate, 4-bromo -3-fluoro -2-methylaniline procurement standard, 5-bromo -4-fluoro -1H-indazole...Read more -
Epoxy compounds-pharmaceutical API and fine chemical core intermediates | 1,2-epoxy dodecane, 1,2-epoxy tetradecane, 1,2-epoxy hexadecane parameters and applications
Meta Description: Epoxy compounds are highly active ternary oxygen heterocyclic pharmaceutical intermediates, which are widely used in the synthesis of raw materials. 1,2-epoxy dodecane, tetradecane and hexadecane are in sufficient stock, stable mass production, high purity, controllable impuriti...Read more -
H1: Virazodone (CAS 163521-12-8) API and Core Synthetic Intermediates | Pharmacological Efficacy, Application Scenarios and Complete Supply Plan
Core Summary vilazodone (CAS 163521-12-8) is the world’s first SPARI dual-mechanism antidepressant drug approved by FDA, specifically for the treatment of adult severe depression with anxiety symptoms. The complete synthesis route of the drug cannot be separated from three key heterocyclic ...Read more -
Esaxerenone (CAS 1632006-28-0) API and Core Synthetic Intermediates: A Comprehensive Analysis
H1 Title: Esaxerenone CAS 1632006-28-0 | Indications, Pharmacological Efficacy, and Complete Set of Key Pharmaceutical Intermediates I. What is Esaxerenone? Quick Answer: Esaxerenone (development code CS-3150) is a third-generation, highly selective nonsteroidal mineralocorticoid receptor antagon...Read more -
Vericiguat (CAS 1350653-20-1): Efficacy, Clinical Applications & Detailed Introduction to Two Core Synthetic Intermediates | 1361232-72-5 / 256504-39-9
Abstract Vericiguat is the world’s first long-acting oral soluble guanylate cyclase (sGC) stimulator, specially indicated for the treatment of chronic heart failure with reduced ejection fraction. It can significantly reduce the risks of cardiovascular death and heart failure hospitalization. ...Read more -
Finerenone CAS.No:1050477-31-0 Pharmacological Efficacy Clinical Application | Full Set of 6 Synthetic Intermediates Supply Parameter Table
Detailed explanation of the mechanism, indications and evidence-based clinical efficacy of finerenone (coretta); Complete display of 6 core intermediates: 4-cyano -2-methoxybenzaldehyde 21962-45-8, 4-amino -5-methyl -2-hydroxypyridine 95306-64-2, 1050477-39-8, 1050477-43-4, 1050477-44-5, 10DMF, G...Read more -
Deuterocactinib (CAS: 1609392-27-9) | TYK2 Inhibitor API, Indications, Efficacy, and Supply Solutions for Three Key Deuterated Intermediates
Deuterocactinib (CAS: 1609392-27-9) | TYK2 Inhibitor API, Indications, Efficacy, and Supply Solutions for Three Key Deuterated Intermediates This article details the clinical applications and pharmacological efficacy of deuterocactinib, along with three core synthetic intermediates: deuter...Read more -
Orforglipron (CAS 2212020-52-3)
Orforglipron (CAS No. 2212020-52-3, development code LY3502970) is the world’s first oral non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly, approved in 2026 for type 2 diabetes mellitus (T2DM) and chronic obesity management. Unlike injectable peptide GLP-1 therapies (semag...Read more
